IBCN 2020: Correlation between BMI, Diabetes Mellitus, and Outcomes in Patients Treated with BCG Immunotherapy for Non Muscle-Invasive Bladder Cancer

(UroToday.com) Dr. Nathan Brooks, Society of Urologic Oncology (SUO) Fellow at the MD Anderson Cancer Center, Houston, Texas, USA presented “Correlation Between Body Mass Index (BMI), diabetes mellitus (DM), and Outcomes in Patients Treated with Bacillus Calmette Guerin (BCG) Immunotherapy for non-muscle-invasive bladder cancer (NMIBC).”  An ‘obesity paradox’ exists in a number of malignancies, characterized by generally poor disease-specific survival but the improved response to immunotherapy. 

Dr. Brooks et al. investigated whether this paradox exists in NMIBC patients treated with intravesical BCG.  On an institutional review of 579 patients treated with at least induction BCG, 75% of patients were overweight or obese.  BMI >25 was associated with a decreased risk of progression.  Similar findings were identified using BMI as a continuous variable.  Indeed, an obesity paradox does appear to exist in NMIBC, and these data have implications on predicting treatment response to intravesical immunotherapy.  Freedom from cystectomy would also be a notable endpoint in this comorbid population.


Presented by: Nathan Brooks, MD, SUO Fellow at the MD Anderson Cancer Center, Houston, TX

Written by: Dr. Patrick Hensley, Urologic Oncology Fellow at MD Anderson Cancer Center, Twitter: @pjhensley11, with Ashish Kamat, MD, MBBS, President of The International Bladder Cancer Network (IBCN), The International Bladder Cancer Group (IBCG), and Professor of the Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas, Twitter: @UroDocAsh, at the International Bladder Cancer Network (IBCN) Annual Meeting, #IBCN2020, October 17, 2020.